Skip to main content

Table 2 Spearman correlation analysis between possible affecting factors and asprosin concentrations in control and T2DM groups

From: Serum concentration of asprosin in new-onset type 2 diabetes

Parameter Control T2DM
r p r p
Age (year) 0.139 0.175 − 0.116 0.269
BMI (mg/k2) 0.454** < 0.001 0.285** 0.006
FBG (mg/dL) 0.720** < 0.001 0.875** < 0.001
HbA1c (%) − 0.076 0.462 0.746** < 0.001
Insulin (mIU/L) − 0.139 0.174 − 0.079 0.454
HOMA-IR − 0.082 0.422 0.214* 0.039
HOMA-β − 0.574** < 0.001 − 0.567** < 0.001
HOMA-S 0.051 0.621 − 0.135 0.198
QUICKI − 0.117 0.255 − 0.522** < 0.001
TC (mg/dL) 0.041 0.691 0.142 0.178
TAG (mg/dL) 0.036 0.729 0.254* 0.015
HDL-C (mg/dL) 0.121 0.239 0.060 0.580
LDL-C (mg/dL) 0.139 0.175 0.074 0.488
LDL-C/HDL-C 0.064 0.537 0.065 0.544
TC/HDL-C − 0.059 0.564 0.214* 0.044
TAG/HDL-C 0.030 0.774 0.205 0.054
  1. Our analysis showed BMI, FBG and, HOMA-β were significantly correlated with the asprosin concentration in both groups. We also found that only in T2DM patient HbA1C, HOMA-IR, QUICKI, TAG and TC/HDL-C are in correlation with asprosin in serum
  2. BMI body mass index, FBG fasting blood sugar, HbA1c hemoglobin A1c, TC total cholesterol, TAG triacylglycerol, HDL-C HDL cholesterol, LDL-C LDL cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, HOMA-β, QUICKI quantitative insulin sensitivity check index and triacylglycerol (TAG) and total cholesterol/HDL cholesterol (TC/HDL-C) ratio